BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:03:31 2024-05-30 am EDT			5-day change	1st Jan Change
92.92 ^USD	-0.33%		-5.49%	-11.35%

May. 29	BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa	MT
May. 29	BioNTech gets $145 mln funding for African vaccine plants	RE

BIONTECH : Deutsche Bank reaffirms its Neutral rating

May 08, 2024 at 10:15 am EDT

Initially Neutral on the company, Deutsche Bank's analyst Emmanuel Papadakis maintained his recommendation. The target price continues to be set at USD 95.

Latest news about BioNTech SE

BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa	May. 29	MT
BioNTech gets $145 mln funding for African vaccine plants	May. 29	RE
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants	May. 29	RE
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	May. 28	MT
BioNTech Collaborating with MediLink to Develop More Potential Antibody-Drug Conjugate, Immunotherapy Treatments	May. 28	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	May. 24	MT
BIONTECH : Deutsche Bank remains Neutral	May. 24	ZD
Health Care Up as Vaccine Makers Gain - Health Care Roundup	May. 22	DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	May. 22	MT
Medigene, BioNTech Extend Cancer Immunotherapy Partnership	May. 21	MT
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	May. 21	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	May. 17	MT
Sector Update: Health Care	May. 17	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	May. 17	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	May. 17	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports	May. 17	RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises	May. 17	MT
Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target	May. 14	MT
BIONTECH : UBS remains Neutral	May. 10	ZD
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	May. 08	MT
BIONTECH : Deutsche Bank reaffirms its Neutral rating	May. 08	ZD

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract Number: 2533

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

86.2 EUR

Average target price

103.1 EUR

Spread / Average Target

+19.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-11.35%	22.5B
VERTEX PHARMACEUTICALS INCORPORATED	+7.48%	114B
REGENERON PHARMACEUTICALS, INC.	+8.46%	104B
ARGENX SE	+0.76%	22.57B
GENMAB A/S	-10.72%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-15.16%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+3.13%	13.55B
SAREPTA THERAPEUTICS, INC.	+26.38%	10.99B
INSMED INCORPORATED	+83.70%	7.96B

Bio Therapeutic Drugs

BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

BIONTECH : Deutsche Bank reaffirms its Neutral rating

Latest news about BioNTech SE

Chart BioNTech SE

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for BioNTech SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs